These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 10555659)

  • 1. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study.
    Metman LV; Del Dotto P; LePoole K; Konitsiotis S; Fang J; Chase TN
    Arch Neurol; 1999 Nov; 56(11):1383-6. PubMed ID: 10555659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.
    Del Dotto P; Pavese N; Gambaccini G; Bernardini S; Metman LV; Chase TN; Bonuccelli U
    Mov Disord; 2001 May; 16(3):515-20. PubMed ID: 11391748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
    Verhagen Metman L; Del Dotto P; van den Munckhof P; Fang J; Mouradian MM; Chase TN
    Neurology; 1998 May; 50(5):1323-6. PubMed ID: 9595981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease.
    Luginger E; Wenning GK; Bösch S; Poewe W
    Mov Disord; 2000 Sep; 15(5):873-8. PubMed ID: 11009193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study.
    Snow BJ; Macdonald L; Mcauley D; Wallis W
    Clin Neuropharmacol; 2000; 23(2):82-5. PubMed ID: 10803797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term antidyskinetic efficacy of amantadine in Parkinson's disease.
    Wolf E; Seppi K; Katzenschlager R; Hochschorner G; Ransmayr G; Schwingenschuh P; Ott E; Kloiber I; Haubenberger D; Auff E; Poewe W
    Mov Disord; 2010 Jul; 25(10):1357-63. PubMed ID: 20198649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
    Oertel W; Eggert K; Pahwa R; Tanner CM; Hauser RA; Trenkwalder C; Ehret R; Azulay JP; Isaacson S; Felt L; Stempien MJ
    Mov Disord; 2017 Dec; 32(12):1701-1709. PubMed ID: 28833562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease].
    Cersósimo MG; Scorticati MC; Micheli FE
    Medicina (B Aires); 2000; 60(3):321-5. PubMed ID: 11050808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.
    Pahwa R; Tanner CM; Hauser RA; Isaacson SH; Nausieda PA; Truong DD; Agarwal P; Hull KL; Lyons KE; Johnson R; Stempien MJ
    JAMA Neurol; 2017 Aug; 74(8):941-949. PubMed ID: 28604926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of Tianqi Pingchan Granule, a compound Chinese herbal medicine, for levodopa-induced dyskinesia in Parkinson's disease: A randomized double-blind placebo-controlled trial.
    Zhang Y; Zhu XB; Zhao Y; Cui GY; Li WT; Yuan CX; Huang JP; Wan Y; Wu N; Song L; Zhao JH; Liang Y; Xu CY; Liu MJ; Gao C; Chen XX; Liu ZG
    J Integr Med; 2024 Sep; 22(5):545-551. PubMed ID: 39060125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
    Pahwa R; Tanner CM; Hauser RA; Sethi K; Isaacson S; Truong D; Struck L; Ruby AE; McClure NL; Went GT; Stempien MJ
    Mov Disord; 2015 May; 30(6):788-95. PubMed ID: 25650051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of gabapentin on the motor response to levodopa: a double-blind, placebo-controlled, crossover study in patients with complicated Parkinson disease.
    Van Blercom N; Lasa A; Verger K; Masramón X; Sastre VM; Linazasoro G
    Clin Neuropharmacol; 2004; 27(3):124-8. PubMed ID: 15190235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study.
    Katzenschlager R; Manson AJ; Evans A; Watt H; Lees AJ
    J Neurol Neurosurg Psychiatry; 2004 Feb; 75(2):295-7. PubMed ID: 14742609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.
    Ory-Magne F; Corvol JC; Azulay JP; Bonnet AM; Brefel-Courbon C; Damier P; Dellapina E; Destée A; Durif F; Galitzky M; Lebouvier T; Meissner W; Thalamas C; Tison F; Salis A; Sommet A; Viallet F; Vidailhet M; Rascol O;
    Neurology; 2014 Jan; 82(4):300-7. PubMed ID: 24371304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of extended-release amantadine in levodopa-induced dyskinesias: a meta-analysis.
    Pajo AT; Espiritu AI; Jamora RDG
    Neurodegener Dis Manag; 2019 Aug; 9(4):205-215. PubMed ID: 31392922
    [No Abstract]   [Full Text] [Related]  

  • 17. Dyskinesias induced by subthalamotomy in Parkinson's disease are unresponsive to amantadine.
    Merello M; Perez-Lloret S; Antico J; Obeso JA
    J Neurol Neurosurg Psychiatry; 2006 Feb; 77(2):172-4. PubMed ID: 16421117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase Ib Randomized Controlled Study to Evaluate the Effectiveness of a Single-Dose of the NR2B Selective N-Methyl-D-Aspartate Antagonist MK-0657 on Levodopa-Induced Dyskinesias and Motor Symptoms in Patients With Parkinson Disease.
    Herring WJ; Assaid C; Budd K; Vargo R; Mazenko RS; Lines C; Ellenbogen A; Verhagen Metman L
    Clin Neuropharmacol; 2017; 40(6):255-260. PubMed ID: 29059133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.
    Blanchet PJ; Konitsiotis S; Chase TN
    Mov Disord; 1998 Sep; 13(5):798-802. PubMed ID: 9756148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease.
    Tanner CM; Pahwa R; Hauser RA; Oertel WH; Isaacson SH; Jankovic J; Johnson R; Chernick D; Hubble J
    J Parkinsons Dis; 2020; 10(2):543-558. PubMed ID: 31929122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.